AGIOS PHARMACEUTICALS, INC. Contract with Customer, Receivable, after Allowance for Credit Loss, Current
AGIOS PHARMACEUTICALS, INC. (AGIO) had Contract with Customer, Receivable, after Allowance for Credit Loss, Current of $20.11 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Contract with Customer, Contract Asset, Contract Liability, and Receivable
us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent · last filed 2026-07-30
- 2026-06-30: Contract with Customer, Receivable, after Allowance for Credit Loss, Current $20.11M.
- 2025-12-31: Contract with Customer, Receivable, after Allowance for Credit Loss, Current $10.58M.
| Period end | Contract with Customer, Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $20.11M 10-Q · filed 2026-07-30 |
| 2025-12-31 | $10.58M 10-Q · filed 2026-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |